Nanomerics has entered into a development agreement with California based NEMUS Bioscience, Inc. (OTCQB: NMUS), to develop a topical ocular formulation of tetrahydrocannabinol-valine-hemisuccinate (THCVHS), the prodrug of THC, which is the active component of Nemus drug candidate NB1111 being developed for the treatment of glaucoma.
Nanomerics today announced that it has licensed the North American rights to NM133 for the treatment of dry eye to IACTA Pharmaceuticals.
At the recent annual International APS PharmSci conference organised by the Academy of Pharmaceutical Sciences, Professor Ijeoma Uchegbu was awarded the Innovative Science Award, sponsored by GSK for her work on translating science into practice.
Nanomerics is pleased to announce a major milestone in toxicology testing of its Molecular Envelope Technology has been completed.
Nanomerics’ scientists have demonstrated that encapsulating chemotherapy drugs within Nanomerics’ MET nanoparticles diverts the drug from the bone marrow, while enabling higher levels of drug to access the brain.
Nanomerics is pleased to announce the strengthening of its Scientific Advisory Board with the appointment of Professor Martin Koltzenburg.
Professor Koltzenburg’s appointment will support the clinical development of Nanomerics' lead product NM0127, a novel pain therapeutic based on an endogenous peptide.